Ocugen (OCGN) vs Protalix BioTherapeutics (DE) (PLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Protalix BioTherapeutics (DE) (PLX) has outperformed Ocugen (OCGN) over the past year, gaining 65.7% versus a loss of 33.8%. Over five years, PLX leads with a +192.9% price change compared with -88.1% for OCGN. Ocugen is the larger company by market cap ($260.6 million vs $244.5 million), about 1.1 times the size.
Protalix BioTherapeutics (DE) converts more of its revenue into profit, with a net margin of -12.5% versus -1537.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OCGN | PLX |
|---|---|---|
| Share price | $0.7679 | $2.90 |
| Market cap | $260.55M | $244.52M |
| 1-day change | +4.79% | -5.23% |
| YTD return | -43.12% | +61.11% |
| 1-year return | -33.80% | +65.71% |
| 5-year return | -88.09% | +192.93% |
| P/E ratio (TTM) | — | 12.08 |
| Forward P/E | — | 4.68 |
| EPS (TTM) | $-0.20 | $0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.41M | $52.74M |
| Revenue growth (YoY) | +8.83% | -1.23% |
| Net income (latest FY) | $-67.85M | $-6.60M |
| Gross margin | — | 48.82% |
| Operating margin | -1425.70% | -10.43% |
| Net margin | -1537.41% | -12.52% |
| 52-week high | $2.73 | $3.19 |
| 52-week low | $0.691 | $1.65 |
| Distance from 52-week high | -71.82% | -9.09% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1484.84% | +313.79% |
| Average volume | 7.34M | 903.48K |
| Shares outstanding | 339.31M | 84.32M |
| Employees | 116 | 226 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLX has outperformed OCGN by 99.5 percentage points over the past year.
- Protalix BioTherapeutics (DE) is more profitable, keeping -12.5 cents of every revenue dollar as net income versus -1537.4 cents for Ocugen.
- Ocugen grew revenue faster in its latest fiscal year (+8.83% vs -1.23%).
About Ocugen
OCGN stock →Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees
OCGN vs PLX FAQ
Which is bigger, Ocugen or Protalix BioTherapeutics (DE)?
Ocugen (OCGN) is larger, with a market capitalization of $260.55M compared with $244.52M for Protalix BioTherapeutics (DE) (PLX).
Which stock has performed better over the past year, OCGN or PLX?
PLX returned +65.71% over the past 12 months, compared with -33.80% for OCGN (price return, excluding dividends). Past performance does not predict future results.
Are Ocugen and Protalix BioTherapeutics (DE) in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.